APhA CAUTIONS AGAINST NEW Rx COMPOUNDING RESTRICTIONS

JUNE 01, 2007

Drug compounding is “a critical component of the American health care system,” according to a statement from the American Pharmacists Association (APhA). Congress should think twice before enacting legislation that would place new limits on the ability of pharmacists to produce compounded pharmaceuticals, the association said in an appeal to the Senate Special Committee on Aging.

Proposals granting the FDA expanded powers to restrict pharmacy’s compounding authority are under active consideration on Capitol Hill. The APhA argued that such limitations would limit health care options for all Americans.

“Compounding allows pharmacists and physicians to address the health care needs of patients who do not fall within the range of commercially available dosage strengths and formulations,” the APhA told Congress.

“Virtually all practicing pharmacists will be involved with compounding activities at some point during their career,” said the association.

APhA is one of 9 pharmacy organizations that sent a joint letter to the expected sponsors of the draft legislation of the Safe Compounding Act of 2007. The group stated that the legislation “would negatively impact patient access to necessary compounded prescription medications and create onerous, new requirements for prescribers and pharmacists.” For a related article, go to www.pharmacytimes.com/compounding.



SHARE THIS SHARE THIS
0
 

Conference Coverage

Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo. 


 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.